MNOV vs. CRDF, FENC, VOR, INBX, CGC, LIMN, ESPR, BTMD, NBTX, and PRQR
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Cardiff Oncology (CRDF), Adherex Technologies (FENC), Vor Biopharma (VOR), Inhibrx Biosciences (INBX), Canopy Growth (CGC), Liminatus Pharma (LIMN), Esperion Therapeutics (ESPR), biote (BTMD), Nanobiotix (NBTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry.
MediciNova vs. Its Competitors
Cardiff Oncology (NASDAQ:CRDF) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.
Cardiff Oncology has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
MediciNova has higher revenue and earnings than Cardiff Oncology. MediciNova is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by company insiders. Comparatively, 13.6% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. MediciNova's average media sentiment score of 0.94 beat Cardiff Oncology's score of 0.62 indicating that MediciNova is being referred to more favorably in the news media.
Cardiff Oncology currently has a consensus target price of $11.70, indicating a potential upside of 164.71%. MediciNova has a consensus target price of $7.00, indicating a potential upside of 473.77%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Cardiff Oncology.
MediciNova has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. MediciNova's return on equity of -20.77% beat Cardiff Oncology's return on equity.
Summary
MediciNova beats Cardiff Oncology on 11 of the 16 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
This page (NASDAQ:MNOV) was last updated on 7/17/2025 by MarketBeat.com Staff
Free MNOV Stock Alerts